Understand the source comparison
AOD-9604 Versus GLP-1: Mechanism, Side Effects, and Use Case Comparison
Primary Mechanism Beta-3 adrenergic receptor activation → hormone-sensitive lipase stimulation → triglyceride breakdown GLP-1/GIP receptor agonism → delayed gastric emptying → reduced appetite signalling → caloric deficit AOD-9604 targets lipolysis directly; G
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Mechanism
- Beta-3 adrenergic receptor activation → hormone-sensitive lipase stimulation → triglyceride breakdown
- GLP-1/GIP receptor agonism → delayed gastric emptying → reduced appetite signalling → caloric deficit
- AOD-9604 targets lipolysis directly; GLP-1 creates caloric restriction through appetite modulation
- Appetite Effect
- None. Does not affect ghrelin, leptin, or satiety hormones
- Significant appetite suppression (primary driver of weight loss)
- Choose GLP-1 if appetite control is the goal; AOD-9604 if fat mobilisation without hunger changes is needed
- Weight Loss Magnitude
- 2.2% mean body weight at 12 weeks (clinical trial)
- 14.9–20.9% at 68–72 weeks depending on dose and agent
- GLP-1 produces 6–9× greater weight reduction in head-to-head comparison
- Lean Mass Preservation
- Preserved. DEXA scans show fat mass reduction without muscle loss
- Muscle loss occurs unless protein intake (1.6–2.2g/kg) and resistance training maintained
- AOD-9604 may be preferable in protocols prioritising body composition over total weight
- Gastrointestinal Side Effects
- None. No gastric slowing or nausea
- Nausea, vomiting, diarrhoea in 30–45% during dose escalation
- AOD-9604 bypasses GI tolerability issues that cause 5–15% of GLP-1 users to discontinue
- Regulatory Status
- Research peptide. Not FDA-approved for obesity treatment
- FDA-approved (Wegovy, Zepbound) or compounded versions available
- GLP-1 has full pharmaceutical backing; AOD-9604 is research-grade only